VNRX

EX-99.1

2 vnrx_ex991.htm

PRESS RELEASE

vnrx_ex991.htm

EXHIBIT 99.1

VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for

Friday, May 15 at 8:30 a.m. U.S. Eastern Time

Henderson, Nevada, May 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces financial results and a business update for the first quarter 2026. Volition management will host a conference call tomorrow, May 15 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below.

Cameron Reynolds, President and Group Chief Executive Officer, said:

“We have made strong progress across all of our product pillars during the first quarter and indeed subsequent to quarter end.

“We announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q® Vet feline prototype assay in detecting lymphoma in cats, our third species. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment. The feline test could greatly expand the market of our Nu.Q® Vet platform.

“We are working with our long-term collaborators at the Hospices Civils de Lyon, one of Europe's leading cancer centers, on the reimbursement submission for Nu.Q® Lung Cancer. Reimbursement is the last step on the path to the first use of Nu.Q® in routine clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives.

“We reported two new, potentially large, clinical use cases for our Nu.Q® NETs assay beyond sepsis. In conjunction with the Mayo Clinic1, we demonstrated Nu.Q® NETs’ potential clinical utility in aiding early risk identification which could inform targeted preventive strategies in acute trauma care. We also demonstrated potential use for patient management of a chronic disease, Hidradenitis Suppurativa,2 which affects about 1% of the world’s population. Both use cases have the potential to be large markets.

“We are currently in discussions with more than a dozen of the world’s leading diagnostic and liquid biopsy companies where our goal is to enter into licensing agreements and other arrangements that will bring revenue in the form of up front milestone payments, royalties and/or other recurring revenue.

“We are delighted to have grown the commercial interest in the first quarter, particularly with regards to our Capture-Seq™ technology, with an increase in discussions, including for technical evaluations.

“Discussions are at various stages of the negotiation process across all our different pillars; our laser focus is on executing licensing agreements and we will update you as they progress.”

1

Financial Highlights

· Revenue for the first quarter was approximately $1.0 million, compared to $0.2 million for the same period in 2025.

· Operating loss was down 3% for the quarter versus the comparable quarter in 2025.

· Net cash used in operating activities was $5.3 million.

· Receipts in the quarter included:

○

$5.4 million in net proceeds from equity sales through our at-the-market facility,

○

$1.9 million in net proceeds from issuance of a convertible note and warrant, and

○

$1 million of non-dilutive funding from agencies of the Walloon Region, with an additional approximate $0.9 million expected to be received in tranches based on certain time and event milestones over the next 12 months.

2

Event:

VolitionRx Limited First Quarter 2026 Earnings and Business Update Conference Call

Date:

Friday, May 15, 2026

Time:

8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time

U.S. & Canada Dial-in: 1-877-407-9716 (toll free)

U.K. Dial-in: 0 800 756 3429 (toll free)

Toll/International: 1-201-493-6779

Conference ID:   13760656

Louise Batchelor, Group Chief Marketing & Communications Officer of Volition will host the call along with Cameron Reynolds, President and Group Chief Executive Officer and Terig Hughes, Group Chief Financial Officer. The call will provide an update on important events that have taken place in the first quarter of 2026, subsequent events and upcoming milestones.

A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until May 29, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13760656.

1.

Navarro, Sergio M. et al, Circulating Nucleosomes Are Elevated In Trauma Patients With Venous Thromboembolism: A Prospective Case-Cohort Study. SHOCK Journal, March 2026

2. PrePrint

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcom

EX-99.1

2 vnrx_ex991.htm

PRESS RELEASE

vnrx_ex991.htm

EXHIBIT 99.1

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for

Wednesday, April 1 at 8:30 a.m. U.S. Eastern Time

Henderson, Nevada, March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces financial results and a business update for the full fiscal year 2025. Volition management will host a conference call tomorrow, April 1 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below.

Cameron Reynolds, President and Group Chief Executive Officer, said:

“We set out over fifteen years ago to help save lives and improve outcomes for millions of patients worldwide, and I could not be prouder of the progress we are making towards that goal.

“In 2025 we not only received our first order for the Nu.Q® Cancer assays for clinical certification ahead of routine clinical use in lung cancer, but we also announced the inclusion of our Nu.Q® NETs assay in a real-world interventional evaluation of early detection of sepsis, in a government-backed program (~$7.3 million) in France.

“Cancer and sepsis are leading causes of death, accounting for approximately one third of deaths worldwide. Our tests are about to be used in both these devastating diseases, to help save lives in real world hospital settings: an extremely proud moment for our entire team.

“Our goal is to secure a range of licensing agreements in the human diagnostics space and to that end we are in discussions with around 10 of the world’s leading diagnostic and liquid biopsy companies and are at various stages of the process across our different pillars, ranging from due diligence to tech transfer, to evaluation of clinical samples, to contract negotiation. We anticipate further human licensing deals and will update on progress as they are completed.

“I believe we will look back on 2025, this first quarter of 2026 and indeed in time, the next few quarters, as transformational for the company.”

Financial Highlights

· Finished the year strongly with year over year revenue growth for Q4 of 133%.

· Full-year revenue for 2025 was $1.7 million, representing growth of 40% over the previous year.

· Operating expenses for the year were down $4.8 million, or 17% compared to last year.

· Net loss was down 14% for the year versus 2024.

· Net cash used in operating activities was $19.7 million for the year, down 24%.

· Subsequent to year end, we received:

○

$5.4 million in net proceeds from equity sales through our at-the-market facility,

○

$1.9 million in net proceeds from issuance of a convertible note and warrant, and

○

$1.0 million of non-dilutive funding from agencies of the Walloon Region, with an additional approximate $0.9 million expected to be received in tranches based on certain time and event milestones over the next 12 months.

1

Event:

VolitionRx Limited Full Fiscal Year 2025 Earnings and Business Update Conference Call

Date:

Wednesday, April 1, 2026

Time:

8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time

U.S. & Canada Dial-in: 1-877-407-9716 (toll free)

U.K. Dial-in: 0 800 756 3429 (toll free)

Toll/International: 1-201-493-6779

Conference ID: 13759627

Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Terig Hughes, Group Chief Financial Officer, Dr. Andrew Retter, Medical Consultant and Dr. Jake Micallef, Chief Scientific Officer. The call will provide an update on important events that have taken place in 2025, subsequent events and upcoming milestones.

A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until April 15, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13759627.

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

Th

vnrx_8k.htm0000093314false00000933142025-11-132025-11-13iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  November 13, 2025

VolitionRx Limited

(Exact name of registrant as specified in its charter)

Delaware

001-36833

91-1949078

(State or other jurisdiction

(Commission

(IRS Employer

of Incorporation)

File Number)

Identification Number)

1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014

(Address of principal executive offices and Zip Code)

+1 (512) 774-8930

(Registrant’s telephone number, including area code )

Not applicable (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on which Registered

Common Stock,par value $0.001 per share

VNRX

NYSE American, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

VOLITIONRX LIMITED

Form 8-K Current Report

Item 2.02. Results of Operations and Financial Condition.

The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

On November 13, 2025, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended September 30, 2025. The Company also confirmed its conference call to be held on November 14, 2025 at 8:30 a.m. U.S. Eastern Time.  Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

99.1

Press Release of VolitionRx Limited, dated November 13, 2025.

104

Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VOLITIONRX LIMITED

Date November 13, 2025 By: /s/ Cameron Reynolds

Cameron Reynolds

Chief Executive Officer & President

3

EXHIBIT INDEX

Exhibit Number

Description

99.1

Press Release of VolitionRx Limited, dated November 13, 2025.

4